Brief: Ocugen, Inc. Announces First Patient Dosed In Phase 2/3 Gardian3 Pivotal Confirmatory Trial For Ocu410st—Novel Modifier Gene Therapy Candidate For Stargardt Disease
18/07/2025 13:28
Ocugen Inc OCGN.O: OCUGEN, INC. ANNOUNCES FIRST PATIENT DOSED IN PHASE 2/3 GARDIAN3 PIVOTAL CONFIRMATORY TRIAL FOR OCU410ST—NOVEL MODIFIER GENE THERAPY CANDIDATE FOR STARGARDT DISEASE OCUGEN INC - PLANS TO SUBMIT BLA FOR OCU410ST IN 2027 Source text: ID:nGNX2DWcZN Further company coverage: OCGN.O